

## Nano Interface Technology Announces Evaluation of its Products in Collaboration with NRL and VCU -- Expanding the Market Success of Nano-Biomaterials Coated Orthopedic and Dental Implants

Lorton, Virginia. April 12, 2006 –Nano Interface Technology, Inc. (NITI) announces evaluation of its product in collaboration with the Naval Research Laboratory (NRL) and the Virginia Commonwealth University (VCU). These leading institutions involved in nanotechnology research are working with the Nano Interface Technology to examine a variety of nano-biomaterials for coating of orthopedic/dental implants and other devices.

NITI has signed a Corporate Research and Development Agreement (CRADA) with NRL related to coatings for orthopedic implants. The collaboration with VCU will address innovative dental applications.

"We are very pleased to sign a CRADA with the NRL because NRL is a pioneer research organization in nanotechnology and has contributed very significantly in the development of several nanotechnology-based products. NITI continues to develop products using its proprietary platform technology; its products are examined through relationships with top government and academic institutions. The new products assessment relationships are solidifying our leadership in commercializing ultra-pure nano-biomaterials for orthopedic and dental applications," stated Dr. C. P. Singh, President & CEO at Nano Interface Technology. "In the nanotechnology arena, only those companies which have slow and steady growth will win the race," he added.

"The collaboration with Nano Interface Technology will accelerate development of better products for orthopedic and dental applications," stated Dr. Peter C. Moon, Director of Dental Biomaterials Laboratory at the Virginia Commonwealth University.

### About Nano Interface Technology, Inc.

NITI is launching a portfolio of products based on ultra-pure nano-biomaterials for medical devices such as hip, knee and dental implants. These nano-biomaterials based devices are scalable and use ultra-pure nano-biomaterials developed using proprietary platform technology. These nano-biomaterials can be applied to a broad range of medical applications where the purity, strength and perfect biocompatibility of biomaterials are paramount for the success rate of such products.